[ad_1]
SAN ANTONIO – (COMMERCIAL THREAD) –Phyton Biotech GmbH, a subsidiary of Phyton, Ltd., today announced that it has filed a patent infringement complaint in the Federal Republic of Germany against Samyang Company, including its subsidiary Samyang Genex Corporation. The main problem with the trial is Samyang’s use of an improved plant cell fermentation technology using cell lines derived from Taxus species to produce paclitaxel. Phyton has developed, patented and commercialized plant cell fermentation technology, and believes that Samyang’s paclitaxel production system violates Phyton’s patented technology.
Among other things, the complaint asks the German court to order Samyang to cease and desist from offering, placing on the market, selling, possessing or in any other way using the active pharmaceutical ingredient. (API) of paclitaxel in the Federal Republic of Germany.
Harald Heckenmueller, Managing Director, said: “Phyton has created many innovations and a number of patents around the fermentation of plant cells and taxanes such as paclitaxel and docetaxel. We intend to vigorously defend our rights under these patents.
About Phyton
Phyton Ltd. is headquartered in San Antonio, Texas, USA, and through its subsidiaries Phyton Biotech GmbH and Phyton Biotech LLC (collectively known as “Phyton Biotech“), is a global supplier of high quality paclitaxel and docetaxel API. With development and manufacturing facilities near Hamburg, Germany and Vancouver, Canada, the company also has R&D capabilities through plant cell fermentation. (PCF â„¢) and chemical synthesis to develop APIs derived from secondary plant metabolites, recombinant proteins or other raw materials for its customers.
[ad_2]
